TUNICRIS-julkaisut - Trepo

Viitteet 1-1 / 1

NSGO-OV-UMB1/ENGOT-OV30: A phase II study of durvalumab in combination with the anti-CD73 monoclonal antibody Oleclumab in patients with relapsed ovarian cancer

Mirza, M. R.; Tandaric, L.; Henriksen, J. R.; Mäenpää, J.; Christensen, R. D.; Waldstrøm, M.; Lindemann, K.; Roed, H.; Auranen, A.; Akslen, L. A.; Thomsen, L. C.V.; Lindberg, S. N.; Madsen, K.; Bjørge, L. (09 / 2024)
article

Objectives: In patients with epithelial ovarian cancer (EOC), the clinical efficacy of monotherapy with immune checkpoint inhibitors (ICIs) against PD-1/PD-L1 is modest. To enhance response rates to these immunotherapeutic ...